| Trial ID: | L1551 |
| Source ID: | NCT01687699
|
| Associated Drug: |
Spironolactone
|
| Title: |
Effects of Spironolactone on Cardio- and Cerebrovascular Morbidity and Mortality in Hemodialysis Patients
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
End-stage Renal Failure
|
| Interventions: |
DRUG: Spironolactone
|
| Outcome Measures: |
Primary: cardio- and cerebrovascular events | Secondary: death from all causes
|
| Sponsor/Collaborators: |
Sponsor: Dialysis Outcomes Heart Failure Aldactone Study Group
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
157
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION
|
| Start Date: |
2008-04
|
| Completion Date: |
|
| Results First Posted: |
|
| Last Update Posted: |
2012-09-19
|
| Locations: |
Shibukawa Clinic, Shizuoka, 424-0053, Japan
|
| URL: |
https://clinicaltrials.gov/show/NCT01687699
|
